Skip to content

PHARMA-BIO SERV, INC.: 10-Q filed 2020-06-15

What PHARMA-BIO SERV, INC. reported in its quarterly report filed 2020-06-15 (fiscal Q2 2020): 33 published measures, 116 facts as tagged in accession 0001654954-20-006640.

This filing

Form
10-Q (quarterly report)
Filed
2020-06-15
Fiscal period
fiscal Q2 2020
Accession
0001654954-20-006640 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PHARMA-BIO SERV, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-04-3028,635,923USD
At 2019-10-3126,633,075USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-04-306,834,262USD
At 2019-10-316,025,569USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-04-3021,801,661USD
At 2020-01-3121,132,403USD
At 2019-10-3120,607,506USD
At 2019-04-3021,357,422USD
At 2019-01-3120,685,771USD
At 2018-10-3120,263,663USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-04-3015,581,997USD
At 2020-01-3115,254,752USD
At 2019-10-3115,490,174USD
At 2019-04-3015,433,111USD
At 2019-01-3115,798,526USD
At 2018-10-3116,029,920USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-02-01 to 2020-04-30687,561USD90
2019-11-01 to 2020-04-301,214,461USD182
2019-11-01 to 2020-01-31526,900USD92
2019-02-01 to 2019-04-30707,483USD89
2018-11-01 to 2019-04-301,178,503USD181
2018-11-01 to 2019-01-31471,020USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-02-01 to 2020-04-30-1,556,707USD90
2019-11-01 to 2020-04-30-41,688USD182
2019-02-01 to 2019-04-30-822,917USD89
2018-11-01 to 2019-04-30-1,040,629USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2020-02-01 to 2020-04-3027,548USD90
2019-11-01 to 2020-04-3038,874USD182
2019-02-01 to 2019-04-3035,761USD89
2018-11-01 to 2019-04-3038,844USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2020-02-01 to 2020-04-305,647,767USD90
2019-11-01 to 2020-04-3010,260,934USD182
2019-02-01 to 2019-04-305,150,344USD89
2018-11-01 to 2019-04-309,716,541USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-04-3020,687,529USD
At 2019-10-3119,473,069USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2020-02-01 to 2020-04-3023,001,627shares90
2019-11-01 to 2020-04-3023,002,745shares182
2019-02-01 to 2019-04-3023,002,903shares89
2018-11-01 to 2019-04-3023,032,107shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2020-02-01 to 2020-04-3023,029,203shares90
2019-11-01 to 2020-04-3023,025,958shares182
2019-02-01 to 2019-04-3023,068,923shares89
2018-11-01 to 2019-04-3023,105,166shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2020-02-01 to 2020-04-3081,407USD90
2019-11-01 to 2020-04-30136,702USD182
2019-02-01 to 2019-04-3075,258USD89
2018-11-01 to 2019-04-30118,213USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-04-30250,752USD
At 2019-10-31290,658USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-02-01 to 2020-04-3011,430USD90
2019-11-01 to 2020-04-3022,860USD182
2019-11-01 to 2020-01-3111,430USD92
2019-02-01 to 2019-04-309,000USD89
2018-11-01 to 2019-04-3018,000USD181
2018-11-01 to 2019-01-319,000USD92

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-02-01 to 2020-04-30720,384USD90
2019-11-01 to 2020-04-301,257,143USD182
2019-02-01 to 2019-04-30476,928USD89
2018-11-01 to 2019-04-30909,429USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-04-3027,141,700USD
At 2019-10-3125,974,980USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-04-302,711,747USD
At 2019-10-313,670,540USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2020-04-309,976,981USD
At 2019-10-318,781,026USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2020-02-01 to 2020-04-300USD90
2019-11-01 to 2020-04-301,699USD182
2019-02-01 to 2019-04-3021,564USD89
2018-11-01 to 2019-04-3087,319USD181

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2020-02-01 to 2020-04-301,868,900USD90
2019-11-01 to 2020-04-303,454,792USD182
2019-02-01 to 2019-04-301,593,402USD89
2018-11-01 to 2019-04-303,072,462USD181

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2020-02-01 to 2020-04-303,778,867USD90
2019-11-01 to 2020-04-306,806,142USD182
2019-02-01 to 2019-04-303,556,942USD89
2018-11-01 to 2019-04-306,644,079USD181

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2020-02-01 to 2020-04-301,148,516USD90
2019-11-01 to 2020-04-302,197,649USD182
2019-02-01 to 2019-04-301,116,474USD89
2018-11-01 to 2019-04-302,163,033USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-04-3023,001,627shares
At 2019-10-3122,995,881shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2020-04-30102,133USD
At 2019-10-31143,600USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2020-04-30874,840USD
At 2019-10-310USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2020-04-30481,325USD
At 2019-10-31509,275USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2020-04-30368,631USD
At 2019-10-31367,437USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2020-02-01 to 2020-04-30768,968USD90
2019-11-01 to 2020-04-301,351,163USD182
2019-02-01 to 2019-04-30782,741USD89
2018-11-01 to 2019-04-301,296,716USD181

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2020-02-01 to 2020-04-30657,828USD90
2019-11-01 to 2020-04-301,172,994USD182
2019-02-01 to 2019-04-30684,216USD89
2018-11-01 to 2019-04-301,163,078USD181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2020-02-01 to 2020-04-3021,579USD90
2019-11-01 to 2020-04-3042,611USD182
2019-02-01 to 2019-04-3021,844USD89
2018-11-01 to 2019-04-3048,682USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2020-02-01 to 2020-04-3048,584USD90
2019-11-01 to 2020-04-3094,020USD182
2019-02-01 to 2019-04-30305,813USD89
2018-11-01 to 2019-04-30387,287USD181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2020-02-01 to 2020-04-30988USD90
2019-11-01 to 2020-04-302,004USD182
2019-02-01 to 2019-04-301,425USD89
2018-11-01 to 2019-04-301,904USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2020-02-01 to 2020-04-302,262,929USD90
2019-11-01 to 2020-04-301,200,788USD182
2019-02-01 to 2019-04-301,212,558USD89
2018-11-01 to 2019-04-301,473,845USD181

Inspect the source

Entity
PHARMA-BIO SERV, INC. / CIK 0001304161
Captured
2026-09-19T11:17:27.241Z
SEC response SHA-256
bc9f33e072a9daa74aa0e8c41fbfef83d107920bc25647db80386f28787f2d49

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001304161.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))